我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

基质金属蛋白酶-2及其抑制物与血管内皮生长因子在小儿先天性心脏病不同肺动脉压力情况下的变化

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2010年第2期
页码:
205-208
栏目:
临床研究
出版日期:
2010-03-04

文章信息/Info

Title:
Role of serum MMP-2, TIMP-1 and VEGF in pulmonary vascular reconstitution in patients with congenital heart disease
作者:
曾红军1; 庞玉生2; 梁秀安2;  陈玉君2
1.广西柳州市妇幼保健院儿科，广西 柳州 545001；2.广西医科大学第一附属医院儿科，广西 南宁 530021
Author(s):
ZENG Hong-jun1;  PANG Yu-sheng2;  LIANG Xiu-an2;  CHEN Yu-jun2
1.Department of Pediatrics, Hospital of Maternal and Child Health, Liuzhou 545001, Guangxi, China; 2.Department of Pediatrics, First Affiliated Hospital, Guangxi Medical University, Nanning 530021, Guangxi, China
关键词:
先天性心脏病; 肺动脉高压; 基质金属蛋白酶; 内皮生长因子; 金属蛋白酶组织抑制物-1
Keywords:
heart defects;  congenital;  pulmonary hypertension;  matrix metalloproteinase;  endothelial growth factor
分类号:
R725.4
DOI:
-
文献标识码:
A
摘要:
目的: 探讨先天性心脏病（以下简称先心病）患儿血清中的基质金属蛋白酶-2(MMP-2)、金属蛋白酶组织抑制物-1（TIMP-1）及血管内皮生长因子(VEGF)在小儿先天性心脏病不同肺动脉压力情况下的变化，予以前列腺素E1（PGE1）治疗和手术对上述因子表达的影响。方法: 将81例左向右分流型先天性心脏病按治疗前肺动脉收缩压（SPAP）分为4组：非肺动脉高压(PH)组16例（SPAP<4.00 kPa）、轻度PH组21例（4.00 kPa≤SPAP<5.33 kPa）、中度PH组21例（5.33 kPa≤SPAP<9.33 kPa）、重度PH组23例（SPAP≥9.33 kPa），以21例正常体检儿为对照组；19例接受前列腺素E1（PGE1）治疗；24例接受手术治疗。用ELISA法检测血清MMP-2、TIMP-1和VEGF的含量，并计算MMP-2/TIMP-1的比值。结果: 与正常组比较，先心病各组MMP-2、VEGF均显著增高（各组MMP-2均P<0.01；VEGF在非、轻、重度PH 3组均P<0.05，中度PH组P<0.01）；TIMP-1的含量均显著增高（轻、中度PH组P<0.05，重度PH组P<0.01）；非PH、轻度PH及中度PH组MMP-2/TIMP-1的比值均显著增高（均P<0.05）。经PGE1药物治疗14 d后，MMP-2、TIMP-1和VEGF的含量与治疗前比较均显著下降（均P<0.01）。手术治疗7 d后，MMP-2、TIMP-1的含量、MMP-2/TIMP-1比值与VEGF的含量均呈显著下降（MMP-2、TIMP-1、VEGF均P<0.01，MMP-2/TIMP-1,P<0.05）。结论: ①左向右分流型先心病血清MMP-2、VEGF显著升高，这可能与先心病肺动脉高压形成及肺血管重构有关。②PGE1可有效地降低先心病并发PH患儿血清MMP-2、 TIMP- 1和 VEGF的表达。③在手术后1周，先心病并发轻、中度PH患儿血清MMP-2、TIMP-1、MMP-2/TIMP-1和VEGF的表达显著降低。
Abstract:
AIM: To investigate the roles of serum matrix metalloproteinase-2 (MMP-2), metalloproteinase inhibition-1 (TIMP-1) and vascular endothelial growth factor (VEGF) in pulmonary vascular reconstitution in patients with congenital heart disease. METHODS: According to the preoperative pulmonary arterial systolic pressure (SPAP), 81 patients with congenital heart disease of left-to-right shunt type were divided into four groups: no pulmonary hypertension (PH) group (n=16, SPAP<4.00 kPa), mild PH group (n=21, 4.00 kPa≤SPAP<5.33 kPa), medium PH group (n=21, 5.33 kPa≤SPAP<9.33 kPa) and severe PH (n=23, SPAP≥9.33 kPa). Twenty one healthy children undergoing routine physical examination were included as the control group. Of the 84 patients, 19 were comprehensively treated with PGE1 and 24 were treated surgically. Concentrations of serum MMP-2, TIMP-1 and VEGF were measured with ELISA and the ratio of MMP-2/TIMP-1 was calculated. RESULTS: Compared with those of the control group, concentrations of serum MMP-2 and VEGF obviously increased in all four groups and the levels of TIMP-1 significantly increased in mild, medium and severe groups. The ratio of MMP-2/TIMP-1 also significantly increased in no PH, mild PH and medium PH groups. After treatment with PGE1 for 14 days, the levels of serum MMP-2, TIMP-1 and VEGF all obviously decreased. Surgical intervention also significantly decreased the levels of MMP-2, TIMP-1, MMP-2/TIMP-1 and VEGF. CONCLUSION: Serum VEGF and MMP-2 may synergistically contribute to pulmonary vascular reconstitution in patients with congenital heart disease of left-to-right shunt type. PGE1 significantly decreases the levels of serum MMP-2, TIMP-1 and VEGF, which may show how PGE1 is involved in reversing pulmonary vascular remodeling. Levels of serum VEGF, MMP-2, MMP-2/TIMP-1 and TIMP-1 decrease significantly 7 days postoperatively.

参考文献/References

［1］ Geiger R, Berger RM, Hess J, et al. Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease［J］. J Pathol, 2000, 191(2):202-207.

［2］ Yao, JS, Chen Y, Zhai W, et al. Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases［J］. Circulation Research, 2004, 95(4):364-371.

［3］ Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase-inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type-I collagen generating the specific 3/4-length and 1/4-length fragments［J］. J Biol Chem, 1995, 270(11):5872-5876.

［4］ Kenagy RD, Vergel S, Mattsson E, et al. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration［J］ . American Thromb Vasc Biol, 1996, 16（11）:1373-1382.

［5］ 马胜军，刘桂清，马增山，等. 先天性心脏病伴肺动脉高压患者血清血管内皮生长因子与肺细小动脉形态变化的关系［J］. 中华心血管病杂志, 2004, 32(1):40-43.

［6］ Hori N , Wiest R, Groszmann RJ. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats［J］. Hepatology, 1998, 28（6）:1467-1475.

［7］ Rabinovitch M, Bothwell T, Hayakawa NB, et al. Pulmonary arterial abnormalities in patients with congenital heart defects and pulmonary hypertension［J］. Lab Invest, 1986, 55(6):632-653.

［8］ Quinn TP, Schlueter M, Soifer SJ, et al. Mechanotransduction in the Lung: Cyclic mechanical stretch induces VEGF and FGF-2 expression in pulmonary vascular smooth muscle cells［J］. Am J Physiol Lung Cell Mol Physiol, 2002, 282(5):897-903.

［9］ Kolpakov V, Rekhter MD, Gordon D, et al. Effect of mechanical forces on growth and matrix protein synthesis in the in vitro pulmonary artery［J］. Circ Res, 1995, 77(4):823-831.

［10］Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention［J］. J Clin Invest, 1999, 103(9):1237-1241.

［11］Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension［J］. Circ Res, 2004, 94(8):1101-1108.

［12］Shen J, He B, Wang B. Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension［J］. Chest, 2005, 128(2):714-719.

［13］Carmosino MJ, Friesen RH, Doran A, et al. Perioperative complications in children with pulmonary hypertension undergoing noncardiac surgery or cardiac catheterization［J］. Anesthesia and Analgesia, 2007, 104 (3): 521-527.

备注/Memo

备注/Memo:
收稿日期：2009-2-12.基金项目：广西回国人员科学基金课题项目资助（桂科回0639025） 通讯作者：庞玉生，教授，主要从事儿科心血管研究Email:pangysh@yahoo.com.cn 作者简介：曾红军，主治医师，硕士Email:gxykzhjun@sina.com
更新日期/Last Update: 2010-03-05